Most readers would already be aware that TG Therapeutics' (NASDAQ:TGTX) stock increased significantly by 49% over the past three months. Since the market usually pay for a company’s long-term ...

A clear picture of TG Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent ...

Breaking Down Analyst Ratings: A Detailed Examination A clear picture of TG Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions.

TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI. The data showed that continued use of BRIUMVI resulted ...

We came across a bullish thesis on TG Therapeutics Inc (TGTX) on ValueInvestorsClub by Bohr. In this article we will summarize the bulls' thesis on TGTX. TG Therapeutics shares were trading at $14 ...

(RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The company said the data ...

NEW YORK - TG Therapeutics, Inc. (NASDAQ: NASDAQ:TGTX) has released updated data from its ENHANCE Phase 3b trial concerning BRIUMVI (ublituximab-xiiy), a treatment for relapsing forms of multiple ...

NEW YORK - TG Therapeutics, Inc. (NASDAQ: NASDAQ:TGTX) has released updated data from its ENHANCE Phase 3b trial concerning BRIUMVI (ublituximab-xiiy), a treatment for relapsing forms of multiple ...

TG Therapeutics' Briumvi shows strong revenue growth, with Q2 2024 revenue up 350% YoY, leading to an upgraded full-year guidance of $290-$300 million. Expansion into CAR-T therapy for autoimmune ...

H.C. Wainwright has reaffirmed its Buy rating and $49.00 price target for shares of TG Therapeutics (NASDAQ: NASDAQ:TGTX). The firm's endorsement follows the recent presentation of new data from ...